Verséa Opthalmics is a division of Verséa Holdings, Inc., a diversified healthcare company committed to transforming scientific discoveries into applicable solutions that are critical to improving patients' lives.

Verséa Opthalmics Team, headed by Dr. Sunil J. Panchal, M.D., Ph.D., the Chief Scientific Officer, focuses on using the latest cutting-edge scientific advancements in regenerative medicine to provide novel treatment solutions that are fully compliant with the new FDA HCT regulations and use the progenerative power of amnion to help solve debilitating eye health conditions that millions are suffering from.

An impressive Portfolio is a result of Verséa's partnership with Celularity, a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies.

Verséa is a trademark of Verséa Holdings, Inc. Verséa is an Exclusive US Distributor for Biovance® 3L Ocular. Biovance® is a registered trademark of Celularity Inc.